Bio-Techne CorpNasdaq: TECH
Health Care · Life Sciences Tools & Services
$55.08
-0.43%
Vol: 1.4M
Research Digest
Friday, May 1, 2026
Bio-Techne Q2 FY2026 flat organic growth; pharma strength offset by macro softness
Bio-Techne reported Q2 FY2026 revenue of $295.9M with flat organic growth but improved margins (+100bps to 31.1%). GAAP EPS $0.24 vs. $0.22 YoY; adjusted $0.46 vs. $0.42. China/APAC region showed strength for third consecutive quarter; large pharma up double-digits fourth quarter in a row. Company benefiting from cost initiatives.
Previous Market Intelligence
13 daysApr 30Bio-Techne advances spatial biology platform; limited recent overnight newsNeutral▶
No significant overnight updates. Bio-Techne announced Ella immunoassay platform CE-IVD marking and SPYRE spatial biology portfolio expansion in Feb-Mar 2026. Recent big tech earnings and AI spending concerns may impact biotech valuations. Next earnings TBD.
Apr 16Bio-Techne faces unusual put option trading (454% above average) on April 10; mixed signalsMixed▶
Bio-Techne Corp (TECH) showed mixed activity in April 2026. On April 10, traders bought 10,003 put options, a 454% surge above typical volume, suggesting bearish positioning. Representative April McClain Delaney disclosed stock sales between $1,001-$15,000 on March 26. Conversely, Sivik Global Healthcare acquired a new $2.65M stake (45,000 shares) in Q4. Zacks upgraded rating to #2 (Buy). Earnings scheduled for May 6, 2026.
Apr 15Bio-Techne faced significant put option buying (454% volume surge) and Evercore ISI lowered price target to $54 from $68.Negative▶
Bio-Techne experienced unusual options trading on April 10, with traders purchasing 10,003 put options—a 454% increase versus typical volume—signaling bearish sentiment. Evercore ISI lowered TECH's price target to $54 from $68 on April 6. The company launched new spatial biology offerings on March 25. Broader tech sector saw strength on April 15 but TECH sentiment remains mixed.
Apr 14Bio-Techne expands spatial biology COMET platform with new SPYRE products; faces bearish options activity.Mixed▶
Bio-Techne expanded its COMET spatial biology portfolio in March with new SPYRE Focus Panels and SPYRE Amplification Kits. Appointed Steve Crouse as President of Diagnostics and Spatial Biology Segment. Stock faces bearish signals including unusually high put option volumes (454% above average). Q2 FY2026 results showed flat revenue of $295.9 million with adjusted EPS of $0.46.
Apr 13Bio-Techne stock declines to $53.80 on heavy put option buying and analyst price target cut.Negative▶
Bio-Techne shares fell to $53.80 with traders buying 10,003 put options (454% above normal volume). Evercore ISI lowered price target from $68 to $54. Consensus analyst rating remains Moderate Buy with average target of $72.77.
Apr 10Bio-Techne stock declined as Evercore ISI downgraded price target from $68 to $54; stock trades at $55.57.Negative▶
Bio-Techne faced analyst headwinds on April 9 when Evercore ISI slashed its price target from $68.00 to $54.00 (-20.59%). The company demonstrated innovation momentum with CE-IVD marking for Ella immunoassay platform and expanded COMET spatial biology portfolio. Consensus rating remains Moderate Buy with $72.77 average target.
Apr 9Bio-Techne expands spatial biology COMET portfolio with enhanced tissue analysis capabilitiesNeutral▶
Bio-Techne (formerly Techne) expanded COMET spatial biology portfolio in March 2026 with new SPYRE Focus Panels, SPYRE Amplification Kits, and upgraded HORIZON image analysis software. Expansion combines validated modular antibody panels with seqLA-based signal amplification for enhanced automated tissue analysis. Company positioned as leading life sciences reagent and instrument provider. Founded 1976, headquartered Minneapolis.
Apr 8No significant overnight updatesNeutral▶
No material news in the last 48 hours.
Apr 7No significant overnight updatesNeutral▶
No material news in the last 48 hours.
Apr 6No significant overnight updatesNeutral▶
No material news in the last 48 hours.
Apr 3No significant overnight updatesNeutral▶
No material news in the last 48 hours. Company celebrating 50th anniversary in 2026. Analyst consensus remains Moderate Buy with price target of $68.58.
Apr 2Bio-Techne expands COMET spatial biology platform with new SPYRE Focus Panels for deeper data interrogation.Neutral▶
Bio-Techne announced expansion of COMET spatial biology solution with new SPYRE Focus Panels and SPYRE Amplification Kits on March 25, 2026. Tools enhance modular, automated workflow with greater sensitivity and flexibility. Company generated $1.2B+ in net sales in FY25. Q2 FY26 results expected with analyst projections of EPS $0.34. Moderate Buy consensus maintained with $68.58 price target.
Apr 1No significant overnight updatesNeutral▶
No material news in the last 48 hours.
Key Fundamentals
RSI (14-Day)
52-Week Range
Moving Averages
Price below 200d MA — bearish structure.